Over a median follow-up of 31 months, patients on SGLT2 inhibitors were associated with a lower risk of hospitalizations for HF or mortality compared to those on DPP4 inhibitors (HR 0.61; 95% CI 0.44–0.85; P = 0.004). Here, SLC5A2 is linked to hydrops fetalis.